Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23199287 | 0.98 | USP2 (0.58) | USP2SMN1; SMN2EPHX2EPHX1ALDH1A1 | |
| SCHEMBL18294 | 0.91 | USP2 (0.69) | USP2SMN1; SMN2EPHX2EPHX1ALDH1A1 | |
| SCHEMBL698803 | 0.91 | USP2 (0.69) | USP2SMN1; SMN2EPHX2EPHX1ALDH1A1 | |
| SCHEMBL28746189 | 0.88 | USP2 (0.56) | USP2SMN1; SMN2EPHX2EPHX1ALDH1A1 | |
| SCHEMBL26669009 | 0.86 | USP2 (0.55) | USP2SMN1; SMN2EPHX2EPHX1ALDH1A1 | |
| SCHEMBL27388627 | 0.84 | USP2 (0.62) | USP2SMN1; SMN2EPHX2EPHX1ALDH1A1 | |
| SCHEMBL16612394 | 0.84 | USP2 (0.62) | USP2SMN1; SMN2EPHX2EPHX1ALDH1A1 | |
| SCHEMBL11339897 | 0.83 | USP2 (0.56) | USP2SMN1; SMN2EPHX2EPHX1ALDH1A1 | |
| SCHEMBL8603867 | 0.83 | — | — | |
| SCHEMBL20617537 | 0.83 | L3MBTL1 (0.53) | USP2SMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| WO-2020198526-A2 | SMALL MOLECULE MODULATORS OF PANK | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2020-10-01 | — | — | WO | disclosed |
| CN-101296914-B | Derivatives with PPAR agonist activity | SHIONOGI & CO | 2012-07-18 | — | — | CN | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| WO-2011142359-A1 | SPIRO COMPOUND AND DRUG FOR ACTIVATING ADIPONECTIN RECEPTOR | 日産化学工業株式会社 (JP) | 2011-11-17 | — | — | WO | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7595318-B2 | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids | ELAN PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| CN-101296914-A | Derivatives with PPAR agonist activity | SHIONOGI & CO (JP) | 2008-10-29 | — | — | CN | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | USP2 2291/4885SMN1; SMN2 4785/4885EPHX2 703/4885 |
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | USP2 4635/4885SMN1; SMN2 4505/4885EPHX2 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.